These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Treatment of mucocutaneous manifestations in Behçet's disease with anakinra: a pilot open-label study. Grayson PC, Yazici Y, Merideth M, Sen HN, Davis M, Novakovich E, Joyal E, Goldbach-Mansky R, Sibley CH. Arthritis Res Ther; 2017 Mar 24; 19(1):69. PubMed ID: 28335798 [Abstract] [Full Text] [Related]
27. Effects of anti-TNF-alpha antibody infliximab in refractory entero-Behcet's disease. Iwata S, Saito K, Yamaoka K, Tsujimura S, Nawata M, Suzuki K, Tanaka Y. Rheumatology (Oxford); 2009 Aug 24; 48(8):1012-3. PubMed ID: 19465589 [No Abstract] [Full Text] [Related]
28. Anti-Tumor Necrosis Factor Therapy in Intestinal Behçet's Disease. Park J, Cheon JH. Gut Liver; 2018 Nov 15; 12(6):623-632. PubMed ID: 29788675 [Abstract] [Full Text] [Related]
34. Behçet's disease - part of the differential diagnosis of ulcerative lesions. Warren S, Alden K, Lomax N. Int J STD AIDS; 2014 Dec 15; 25(14):1044-6. PubMed ID: 24676131 [Abstract] [Full Text] [Related]
35. [Infliximab treatment trial in a patient with neuro-Behçet's disease unresponsive to other treatments]. Kadowaki S, Matsuda N, Moriya A, Ebitani M, Yoshihara A, Nakamura K, Mochizuki H, Ugawa Y. Rinsho Shinkeigaku; 2011 Apr 15; 51(4):261-6. PubMed ID: 21595295 [Abstract] [Full Text] [Related]
39. Clinical manifestations and anti-TNF alpha therapy of juvenile Behçet's disease in Taiwan. Hu YC, Yang YH, Lin YT, Wang LC, Yu HH, Lee JH, Chiang BL. BMC Pediatr; 2019 Jul 11; 19(1):232. PubMed ID: 31296171 [Abstract] [Full Text] [Related]